If you’re paying attention even a little bit to the diversity of the biotech C-suite, it’s easy to see that there are few women or visible minorities at the top. But just how bad is the situation?

As Gilead works with Merck to combine their long-acting HIV drugs, the antiviral giant is hustling its prospect as a single therapy to the FDA. The treatment, lenacapavir, could become a new hope for patients whose infection has evaded current treatments and who have few other options.

When a person needs a thorough heart evaluation, a powerful MRI is rarely at the top of anyone’s list. It can be cumbersome and typically requires the patient to lie still within the scanner’s bore for about an hour as dozens of chest images are taken and processed. Move too much, and the process starts over.

Anavex’s Parkinson’s disease treatment beat placebo at slowing the progression of motor and non-motor symptoms, a benefit that correlated with an increase in SIGMAR1, the drug’s target and the biomarker the company will use to forecast its efficacy. Anavex will now submit the phase 2 data to the FDA to figure out the drug’s path forward.

Drugs that slow tumor growth by targeting genetic abnormalities in the cancer itself are now well established in oncology. But what if doctors could treat cancer by altering gene activity throughout the body, tricking it into fighting off the disease?

Hanmi Pharmaceutical may no longer have a diabetes partner in Sanofi, but newly released results for its GLP-1 drug could move the needle for Type 2 diabetes patients with a history of cardiovascular disease, kidney disease or both. Efpeglenatide reduced the risk of heart attack, stroke and death and also slowed the decline in patients’ kidney function, new data show.

Though the review of its six-month implantable glucose sensor has faced delays at the FDA during the COVID-19 pandemic, Senseonics was able to deliver clinical data on its accuracy at two diabetes meetings this month.

The latest medical device developed by Florida-based incubator Syntheon wasn’t acquired by a medtech giant like Johnson & Johnson, Boston Scientific or Edwards—as many of its past offerings have been—but will instead serve as the basis for an entirely new startup.

The final results from a Grail study of its cancer-tracing blood test found it was accurate at detecting a range of different tumors at early stages—especially those more likely to be lethal and have fewer screening options.

Ten months after saying its losmapimod treatment had performed no better than placebo in an interim analysis, Fulcrum Therapeutics once again has said the oral drug failed to meet the primary endpoint.